A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

The American Journal of Cardiology

Abstract

A randomized, controlled, double-blind trial in 672 hypercholesterolemic patients evaluated the efficacy and safety profile of lovastatin and pravastatin across their usually recommended dosage ranges (lovastatin 20 to 80 mg/day and pravastatin 10 to 40 mg/day). After a 7-week placebo and diet run-in period, patients with low-density lipoprotein (LDL) cholesterol > 160 mg/dl (4.1 mmol/liter) were randomized to 20 mg/day of lovastatin, or 10 mg/day of pravastatin for 6 weeks. The doses were then increased to 40 and 80 mg/day of lovastatin, and 20 and 40 mg/day of pravastatin at weeks 6 and 12, respectively. Efficacy and safety evaluations were performed at weeks 6, 12 and 18. The mean percent changes from baseline in LDL cholesterol at weeks 6, 12 and 18 were -28, -33 and -39%, respectively, with lovastatin, and -19, -25 and -27%, respectively, with pravastatin. All changes were significantly different from 0 (p < 0.001), and the between-group differences were highly significant (p < 0.001). The frequency of adverse events leading to discontinuation was low (2.9% with lovastatin, and 2.4% with pravastatin), with no significant differences between groups. Across the recommended dosage ranges, lovastatin was more effective than pr...Continue Reading

References

Feb 1, 1992·Journal of Clinical Pharmacology·P J PentikainenJ D Rogers
Jul 1, 1992·Clinical Pharmacology and Therapeutics·S P Spielberg, J A Tobert
Dec 1, 1991·Clinical Pharmacology and Therapeutics·A N VgontzasK L Tyson
May 1, 1990·Annals of Internal Medicine·B G JacobP Schwandt
Jul 7, 1988·The New England Journal of Medicine·S M Grundy
Jan 1, 1988·Journal of Clinical Epidemiology·C D JenkinsR M Rose
Jul 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A W AlbertsJ Springer
Aug 15, 1996·The American Journal of Cardiology·T AshrafL Radican
Aug 15, 1996·The American Journal of Cardiology·L M PrisantA Langendörfer

❮ Previous
Next ❯

Citations

Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Apr 15, 1995·The American Journal of Cardiology·J A Tobert
Jan 1, 1995·Experimental Eye Research·J S MacDonald
Jan 29, 2000·Journal of Clinical Pharmacy and Therapeutics·A Jardine, H Holdaas
Aug 5, 2011·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·Raymond Q MigrinoJohn F LaDisa
Nov 7, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Pang H ChongCory Franklin
Jun 20, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Plans-Rubió
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Plans-Rubió
May 22, 2004·Journal of Clinical Pharmacy and Therapeutics·J Caballero, M Nahata
May 12, 2010·Journal of Clinical Pharmacy and Therapeutics·T-C WengS-H Tai
Feb 15, 1994·The American Journal of Cardiology·M R Goldstein
Mar 1, 1994·The American Journal of Medicine·J A Tobert
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Fiona TaylorShah Ebrahim
Sep 4, 1997·Journal of Health Services Research & Policy·S MorrisD Pettitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.